SVB Wealth’s Arcutis Biotherapeutics ARQT Stock Holding History

SVB Wealth’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-262	Closed	-$4.1K	–	550
2025 Q1	$4.1K	Buy	+262	New	+$3.69K	﹤0.01%	1075

Other funds holding ARQT

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

SVB Wealth's ARQT Position: Q2 2025 in Review

SVB Wealth sold out of Arcutis Biotherapeutics (ARQT) in Q2 2025, closing a stake of 262 shares — an estimated $4.1K sold.

SVB Wealth first reported a position in ARQT in Q1 2025 and held it in 1 quarter. The position peaked at $4.1K in Q1 2025. 230 funds tracked by Wall St. Rank hold ARQT as of Q2 2025.

SVB Wealth reported no remaining Arcutis Biotherapeutics position as of Q2 2025 after selling out during the quarter.
SVB Wealth sold 262 Arcutis Biotherapeutics shares in Q2 2025, an estimated $4.1K.
SVB Wealth first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 1 quarter.
SVB Wealth's Arcutis Biotherapeutics position peaked at $4.1K in Q1 2025.
230 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2025.

Based on SVB Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.